Metformin
| Evidence Level: L5 | Predicted Indications: 5 |
Table of Contents
Metformin: From Type 2 Diabetes to Classic Stiff Person Syndrome
One-Sentence Summary
Metformin is a widely marketed oral glucose-lowering drug. The US license records in the data carry no indication text, so “Type 2 diabetes” here is general drug knowledge rather than data from the pack. The TxGNN model predicts it may be effective for classic stiff person syndrome. There are currently 0 clinical trials and 0 publications supporting this direction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Predicted New Indication | Classic stiff person syndrome |
| TxGNN Prediction Score | 99.45% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 20 (the sampled licenses are ANDAs) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Metformin is a long-established antidiabetic, and its mechanistic link to stiff person syndrome has not been documented or verified.
A speculative link is metformin’s AMPK-mediated immunomodulation. Stiff person syndrome is an autoimmune condition, typically associated with anti-GAD65 antibodies. This idea is a hypothesis only.
The TxGNN score of 0.994 is a model output, not clinical evidence. The closely related “focal stiff limb syndrome” received the identical score (0.9945). This suggests the prediction comes from a shared knowledge-graph neighborhood (disease-class similarity) rather than independent drug-specific evidence.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| ANDA201991 | METFORMIN HYDROCHLORIDE | Tablet, extended release | Northwind Health Company, LLC |
| ANDA077078 | METFORMIN HYDROCHLORIDE | Tablet, extended release | Zydus Lifesciences Limited |
| ANDA211052 | METFORMIN HYDROCHLORIDE | Tablet, extended release | Epic Pharma, LLC |
| ANDA209674 | Metformin | Tablet, extended release | Ingenus Pharmaceuticals, LLC |
| ANDA202917 | Metformin Hydrochloride | Tablet, film coated, extended release | Sun Pharmaceutical Industries, Inc. |
Approved indication text was not provided for these licenses. All listed products are oral formulations.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or literature (L5, model prediction only). The mechanism is undocumented, and the identical score for a neighboring disease points to class-level similarity rather than drug-specific signal. The same pattern applies to the other four predicted indications (focal stiff limb syndrome, opsismodysplasia, thiamine-responsive dysfunction syndrome, drug-induced localized lipodystrophy), which are also L5 with no evidence.
To proceed, the following is needed:
- Package insert warnings and contraindications (a blocking gap for safety screening)
- Mechanism of action data (e.g., from DrugBank) to test the AMPK/immunomodulation hypothesis
- A literature and trial search for metformin in stiff person syndrome, including preclinical or case-level evidence
- Route compatibility and similarity-to-original-indication assessment (both currently pending)
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any clinical use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.